The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Extrahepatic causes of death in cirrhosis compared to other chronic conditions in the United States, 1999-2017
Ann Hepatol. 2021 Dec;26:100565. doi: 10.1016/j.aohep.2021.100565. Epub 2021 Oct 30.
Baylor University Medical Center, Dallas, TX, USA. Electronic address: Nagasri.Shankar1@bswhealth.org.
Baylor University Medical Center, Dallas, TX, USA. Electronic address: Azaan.Ramani1@BSWHealth.org.3
Baylor University Medical Center, Dallas, TX, USA. Electronic address: Connor.Griffin@BSWHealth.org.
The University of Tennessee Health Science Center, Saint Louis University, MO, USA. Electronic address: Uagbim@uthsc.edu.
Stanford University School of Medicine, Stanford, CA, USA. Electronic address: Dhkimmd@stanford.edu.
Stanford University School of Medicine, Stanford, CA, USA. Electronic address: Aijazahmed@stanford.edu.
Baylor University Medical Center, Dallas, TX, USA. Electronic address: Sumeet.Asrani@BSWHealth.org.
Abstract
Introduction and objectives: Cirrhosis-related mortality is underestimated and is increasing; extrahepatic factors may contribute. We examined trends in cirrhosis mortality from 1999-2017 in the United States attributed to liver-related (varices, peritonitis, hepatorenal syndrome, hepatic encephalopathy, hepatocellular carcinoma, sepsis) or extrahepatic (cardiovascular disease, influenza and pneumonia, diabetes, malignancy) causes, and compared mortality trends with congestive heart failure (CHF) and chronic obstructive pulmonary disease (COPD) populations.
Materials and methods: A national mortality database was used. Changes in age-standardized mortality over time were determined by joinpoint analysis. Average annual percentage change (AAPC) was estimated.
Results: Cirrhosis cohort: From 1999-2017, both liver-related (AAPC 1.3%; 95% confidence interval [CI] 0.7-1.9) and extrahepatic mortality (AAPC 1.0%; 95% CI 0.7-1.2) increased. Cirrhosis vs other chronic disease cohorts: changes in all-cause mortality were higher in cirrhosis (AAPC 1.0%; 95% CI 0.7-1.4) than CHF (AAPC 0.1%; 95% CI -0.5- 0.8) or COPD (AAPC -0.4%; 95% CI -0.6- -0.2). Sepsis mortality was highest in cirrhosis (AAPC 3.6%, 95% 3.2- 4.1) compared to CHF (AAPC 0.6%, 95% CI -0.5- 1.7) or COPD (AAPC 0.8%, 95% CI 0.5- 1.2). Cardiovascular mortality increased in cirrhosis (AAPC 1.3%, 95% CI 1.1- 1.5), declined in CHF (AAPC -2.0%, 95% CI -5.3- 1.3) and remained unchanged in COPD (AAPC 0.1%, 95% CI -0.2- 0.4). Extrahepatic mortality was higher among women, rural populations, and individuals >65 years with cirrhosis.
Conclusions: Extrahepatic causes of death are important drivers of mortality and differentially impact cirrhosis compared to other chronic diseases.